autologous dendritic cells pulsed with multiple neoantigen peptides.
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 19, 2021 (NCT05059821)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04968366 | Phase 1 | Aug 31, 2021 | Capital Medical University, Guangdong Zhongsheng Pharmaceutical Co., Ltd. |
| NCT05059821 | Phase 1 | Apr 19, 2021 | Ain Shams University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ain Shams University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Guangdong Zhongsheng Pharmaceutical Co., Ltd. | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1